Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.93 +0.39 (+0.67%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

44 45 Next >

Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots ↗

June 26, 2024

After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease.

Via Investor's Business Daily

Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗

June 26, 2024

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

Via Benzinga

UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract ↗

June 24, 2024

Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers.

Via Benzinga

Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer ↗

June 20, 2024

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

Via Benzinga

Topics Lawsuit

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs ↗

June 18, 2024

Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products.

Via Benzinga

Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

June 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

7 A-Rated Biotech Stocks Worth Betting on in June ↗

June 14, 2024

A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.

Via InvestorPlace

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition ↗

June 11, 2024

Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.

Via InvestorPlace

Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

June 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK ↗

June 10, 2024

If approved, this would be the first combination vaccine based on mRNA technology to hit the market.

Via Investor's Business Daily

US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

June 07, 2024

From GSK plc

Via Business Wire

The 3 Most Undervalued Pharma Stocks to Buy in June 2024 ↗

June 06, 2024

These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.

Via InvestorPlace

Topics Economy

Large Cap BIopharmaceuticals Overview ↗

June 03, 2024

As a defensive play healthcare is weighted at about 12% of the S&P 500.

Via Talk Markets

Topics Stocks

GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know. ↗

June 03, 2024

Investors in GlaxoSmithKline are seeing a lot of red on their screens today, as GSK stock falls more than 8% on big legal news.

Via InvestorPlace

Topics Lawsuit

GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma ↗

June 03, 2024

GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or...

Via Benzinga

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 03, 2024

Via Benzinga

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗

June 03, 2024

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022...

Via Benzinga

Topics Lawsuit

GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 03, 2024

Via Benzinga

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

June 03, 2024

From GSK plc

Via Business Wire

Is Moderna Stock a Buy Now That It's a 2-Product Company? ↗

June 03, 2024

The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.

Via The Motley Fool

Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

June 03, 2024

Via Benzinga

Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

June 02, 2024

From GSK plc

Via Business Wire

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK ↗

May 31, 2024

Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years.

Via Investor's Business Daily

AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report ↗

May 27, 2024

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

Via Benzinga

Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit ↗

May 24, 2024

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence.

Via Benzinga

Topics Lawsuit

First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential ↗

May 22, 2024

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.

Via Benzinga

GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims ↗

May 21, 2024

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen,...

Via Benzinga

Topics Lawsuit Whistleblower

GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows ↗

May 21, 2024

GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.

Via Benzinga

GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale ↗

May 17, 2024

GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.

Via Benzinga

Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗

May 16, 2024

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Starting at $3.75/week.

Subscribe Today